3PBIOVIAN will provide Rokote Laboratories with Drug Substance and Drug Product to bring the intranasal FINCoVac 2.1 vaccine into Phase I clinical studies. The FINCoVac 2.1 vaccine aims to elicit a strong mucosal immune response in the nasopharyngeal cells, which serve as the primary entry point for the SARS-CoV-2 causing COVID-19 (coronavirus disease 2019). Such…
Stockholm, Sweden 04/11/2024 – 06/11/2024
Basel, Switzerland 15/10/2024 – 17/10/2024
Milan Italy 08/10/2024 – 10/10/2024
Boston USA 23/09/2024 – 26/09/2024
Boston USA 19/08/2024- 22/08/2024
Biovian and 3P Biopharmaceuticals (“3P”), two leading biologics Contract Development and Manufacturing Organizations (CDMOs), announced today their combination to establish a new pan-European leader in their field.
03/06/2024 – 06/06/2024
At the International Congress of High Impact Entrepreneurship, orchestrated by the European Business and Innovation Center of Navarra (CEIN), 3P Biopharmaceuticals (3P) emerges as the winner of the “Best Track Record in the CEIN incubators” award
Biovian, a one-stop-shop biopharmaceutical CDMO from Turku, Finland proudly announces the successful completion of its debt refinancing initiative and the securing of new funding package to support GeneCity facility expansion.
Biovian, a leading biopharmaceutical CDMO from Finland, uncovers the stonemasonry work of its new manufacturing facility, GeneCity.
This afternoon Pamplona became the epicentre of knowledge and innovation in the field of biomedicine, thanks to the event “Exploring our shared legacy between Neanderthals and Sapiens: challenges and uncertainties of future biomedicine”, organized by 3P Biopharmaceuticals in collaboration with the Faculty of Pharmacy and Nutrition of the University of Navarra.
As part of World Cerebral Palsy Day, 3P Biopharmaceuticals is extremely proud to celebrate its ongoing commitment to inclusion and social development through this valuable collaboration with Aspace’s industrial laundry.
Toleranzia is at the forefront of innovation with their groundbreaking candidate, TOL2, designed to address the autoimmune neuromuscular disease, Myasthenia Gravis (MG).
Biovian, a leading contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, has announced a major investment of over €50 million to expand its manufacturing facility in Turku, Finland.
The Navarre biological CDMO inaugurates its first commercial office in Boston, supported by Keensight Capital
The process transfer and GMP supply of the FGF-1 candidate have been achieved successfully by both companies.
During the meeting, attendees evaluated 3P’s trajectory and its investment plan for the next five years.
This blog post introduces Biovian’s in-house Solution preparation team that primarily focuses on the latter definition, although the other two are present in their daily work as well.
The biotechnology company from Navarra opens its third installation in Noáin.